Search Results - "Vimalnath, K"

[64Cu]Copper chloride PET-CT: a comparative evaluation of fasting and non-fasting states in patients of prostate carcinoma by Kalshetty, Ashwini, Nazar, Aamir, Vimalnath, K V, Chakravarty, Rubel, Chakraborty, Sudipta, Basu, Sandip

“…Altered copper metabolism in cancer has been linked to increased intracellular copper uptake mediated by human copper transporter 1, with [64Cu]Cu2+ as a…”
Get full text

Normal physiological distribution and tumor localization of 64CuCl2 in different human malignancies along with semiquantitative scoring: a comparative evaluation with 18Fluorodeoxyglucose (18FDG) PET-CT by Baberwal, Parth, Sonavane, Sunita, Vimalnath, K V, Chakravarty, Rubel, Chakraborty, Sudipta, Basu, Sandip

“…This study aimed to explore 64-Copper-Chloride (64CuCl2) PET-CT in various malignancies and demonstrate a head-to-head comparison of uptake on 64CuCl2…”
Get full text

Ce‐141‐labeled DOTMP: A theranostic option in management of pain due to skeletal metastases by Vimalnath, K.V., Rajeswari, Ardhi, Sarma, Haladhar Dev, Dash, Ashutosh, Chakraborty, Sudipta

“…Owing to its favorable radioactive decay characteristics (T1/2 = 32.51 d, Eβ [max] = 434.6 keV [70.5%] and 580.0 keV [29.5%], Eγ = 145.4 keV [48.5%]), 141Ce…”
Get full text

Facile synthesis of a Pt(IV) prodrug of cisplatin and its intrinsically 195mpt labeled analog: A step closer to cancer theranostic by Sharma, K, Vimalnath, K, Phadnis, Prasad, Chakravarty, Rubel, Chakraborty, Sudipta, Dash, Ashutosh, Vatsa, Rajesh

“…Background, Aims and Objectives: Cisplatin is extensively used in chemotherapy for treatment of a broad range of cancers. But its undesired side reactions with…”
Get full text

Evaluation of (177)Lu-CHX-A''-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers by Kameswaran, Mythili, Pandey, Usha, Gamre, Naresh, Vimalnath, K V, Sarma, Haladhar Dev, Dash, Ashutosh

“…This study aimed at the preparation and evaluation of (177)Lu-CHX-A''-DTPA-Bevacizumab for targeting VEGF over-expressing cancers. Bevacizumab conjugated to…”
Get full text

Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor by Chakraborty, Sudipta, Chakravarty, Rubel, Shetty, Priyalata, Vimalnath, K V, Sen, Ishita B, Dash, Ashutosh

“…Targeted radionuclide therapy using (177) Lu-labeled peptidomimetic inhibitor of prostate specific membrane antigen (PSMA) viz. PSMA-617 is emerging as one the…”
Get full text

Synthesis and Preclinical Evaluation of (177)Lu-CHX-A"-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma by Kameswaran, Mythili, Pandey, Usha, Dhakan, Chetan, Pathak, Kamal, Gota, Vikram, Vimalnath, K V, Dash, Ashutosh, Samuel, Grace

“…Radioimmunotherapy is a feasible treatment modality for B-cell lymphomas expressing CD20 antigen. Tagging of anti-CD20 monoclonal antibody with a β(-) emitter…”
Get more information

One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [ 177 Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting by Basu, Sandip, Chakraborty, Sudipta, Parghane, Rahul V, Kamaldeep, Ranade, Rohit, Thapa, Pradeep, Asopa, Ramesh V, Sonawane, Geeta, Nabar, Swapna, Shimpi, Hemant, Chandak, Ashok, Vimalnath, K V, Ostwal, Vikas, Ramaswamy, Anant, Bhandare, Manish, Chaudhari, Vikram, Shrikhande, Shailesh V, Sirohi, Bhawna, Dash, Ashutosh, Banerjee, Sharmila

“…The present treatise chronicles one decade of experience pertaining to clinical PRRT services in a large-volume tertiary cancer care centre in India delivering…”
Get full text

Hydroxyapatite (HA) microparticles labeled with (32)P - A promising option in the radiation synovectomy for inflamed joints by Rajeswari, A, Vimalnath, K V, Sarma, H D, Shetty, Priyalata, Mohammed, Shahiralm Khan, Nuwad, Jitendra, Chakraborty, Sudipta, Dash, Ashutosh

“…In the present article we describe a systematic approach pursued for the synthesis of (32)P-labeled hydroxyapatite (HA) microparticles (1-10µm size range)…”
Get full text

Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer by Chakraborty, Sudipta, Sarma, H D, Vimalnath, K V, Pillai, M R A

“…Integrin αvβ3 plays a significant role in angiogenesis during tumor growth and metastasis, and is a receptor for the extracellular matrix proteins with the…”
Get full text

Barium titanate microparticles as potential carrier platform for lanthanide radionuclides for their use in the treatment of arthritis by Chakraborty, Sudipta, Vimalnath, K.V., Sharma, Jyothi, Shetty, Priyalata, Sarma, H.D., Chakravarty, Rubel, Prakash, Deep, Sinha, P.K., Dash, Ashutosh

“…Since the inception of radiation synovectomy, a host of radioactive colloids and microparticles incorporating suitable therapeutic radionuclides have been…”
Get full text

Prospects of medium specific activity 177Lu in targeted therapy of prostate cancer using 177Lu-labeled PSMA inhibitor by Chakraborty, Sudipta, Chakravarty, Rubel, Shetty, Priyalata, Vimalnath, K. V., Sen, Ishita B., Dash, Ashutosh

“…Targeted radionuclide therapy using 177Lu‐labeled peptidomimetic inhibitor of prostate specific membrane antigen (PSMA) viz. PSMA‐617 is emerging as one the…”
Get full text

Radiolanthanide-labeled HA particles in the treatment of rheumatoid arthritis: ready-to-use cold kits for rapid formulation in hospital radiopharmacy by Chakraborty, Sudipta, Vimalnath, K. V., Rajeswari, A., Sarma, H. D., Shinto, Ajit, Radhakrishnan, E. R., Dash, Ashutosh

“…Hydroxyapatite (HA) [Ca 10 (PO 4 ) 6 (OH) 2 ] particles radiolabeled with a variety of β − emitting lanthanide radionuclides and also pseudolanthanide 90 Y…”
Get full text

A versatile technique for radiochemical separation of medically useful no-carrier-added (nca) radioarsenic from irradiated germanium oxide targets by Chattopadhyay, Sankha, Pal, Sujit, Vimalnath, K.V., Das, M.K.

“…A method for the separation of no-carrier-added (nca) arsenic radionuclides from bulk amounts of irradiated germanium oxide (GeO 2) target was developed in…”
Get full text

Preparation, evaluation, and first clinical use of 177Lu-labeled hydroxyapatite (HA) particles in the treatment of rheumatoid arthritis: utility of cold kits for convenient dose formulation at hospital radiopharmacy by Chakraborty, Sudipta, Vimalnath, K. V., Rajeswari, A., Shinto, Ajit, Sarma, H. D., Kamaleshwaran, K., Thirumalaisamy, P., Dash, Ashutosh

“…While radiation synovectomy (RSV) constitutes a successful paradigm for the treatment of arthritis, a major cornerstone of its success resides in the selection…”
Get full text

High purity materials as targets for radioisotope production: Needs and challenges by Shivarudrappa, V, Vimalnath, K V

“…Radionuclides have become powerful and indispensable tools in many endeavours of human activities, most importantly in medicine, industry, biology and…”
Get full text

Studies on preparation of 64Cu using (n,γ) route of reactor production using medium flux research reactor in India by Vimalnath, K. V., Rajeswari, A., Chirayil, Viju, Sharad, P. L., Jagadeesan, K. C., Joshi, P. V., Venkatesh, Meera

“…64 Cu (t 1/2 12.7 h) is a versatile radionuclide owing to its unique decay scheme and exhibits three types of decay electron capture (41%), β − (40%), β +…”
Get full text

Reactor produced [64Cu]CuCl2 as a PET radiopharmaceutical for cancer imaging: from radiochemistry laboratory to nuclear medicine clinic by Chakravarty, Rubel, Shetty, Priyalata, Nair, K. V. Vimalnath, Rajeswari, Ardhi, Jagadeesan, K. C., Sarma, Haladhar Dev, Rangarajan, Venkatesh, Krishnatry, Rahul, Chakraborty, Sudipta

“…Objective Copper-64 is a useful theranostic radioisotope that is attracting renewed interest from the nuclear medicine community in the recent times. This…”
Get full text

(90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation by Chakravarty, Rubel, Chakraborty, Sudipta, Sarma, Haladhar Dev, Nair, K V Vimalnath, Rajeswari, Ardhi, Dash, Ashutosh

“…Radiolabelled monoclonal antibodies (mAbs) are increasingly being utilized in cancer theranostics, which is a significant move toward tailored treatment for…”
Get full text

Clinical scale synthesis of intrinsically radiolabeled and cyclic RGD peptide functionalized 198Au nanoparticles for targeted cancer therapy by Chakravarty, Rubel, Chakraborty, Sudipta, Guleria, Apurav, Kumar, Chandan, Kunwar, Amit, Nair, K.V. Vimalnath, Sarma, Haladhar Dev, Dash, Ashutosh

“…The emerging concept of intrinsically radiolabeled nanoparticles has the potential to transform the preclinical and clinical studies by improving the in vivo…”
Get full text